지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 776 - 783 (8page)
이용수
초록· 키워드
오류제보하기
Background/Aims: The aim of this study was to evaluate the estimated glomerular filtration rate (eGFR) during telbivudine (LdT) versus entecavir (ETV) treatment in chronic hepatitis B (CHB) patients with underlying comorbidities such as diabetes mellitus (DM), hypertension, and cirrhosis. Methods: From 2010 to 2012, 116 CHB patients treated with LdT and 578 treated with ETV were compared in this real-practice cohort. The mean changes in eGFR (Modification of Diet in Renal Disease [MDRD] formula) from baseline to months 6, 12, and 18 were analyzed using a linear mixed model. Results: In LdT-treated patients, the mean eGFR increased by 7.6% at month 18 compared with the eGFR at baseline (MDRD formula in mL/min/1.73 m2). However, in ETV-treated patients, the mean eGFR decreased by 4.1% at month 18 compared with the eGFR at baseline. In the LdT-treated patients with DM, hypertension, cirrhosis or low eGFR <90 mL/min/1.73 m2, the mean eGFR showed a steady improvement, whereas the mean eGFR was reduced in the same subgroups of ETV-treated patients. Conclusions: The eGFR gradually increased over time during LdT treatment, especially in patients with mild abnormal eGFR at baseline, and in those with DM, hypertension, and cirrhosis, whereas a reduction in eGFR was seen with ETV treatment.
목차
등록된 정보가 없습니다.
참고문헌 (40)
참고문헌 신청
Chang TT / 2010 / Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B / Hepatology 51:422~430
Gish RG / 2007 / Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B / Gastroenterology 133:1437~1444
Lai CL / 2007 / Telbivudine versus lamivudine in patients with chronic hepatitis B / N Engl J Med 357:2576~2588
Zeuzem S / 2009 / Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B / J Hepatol 51:11~20
Park H / 2013 / Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir / World J Gastroenterol 19:7671~7679
Gish RG / 2007 / Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B / Gastroenterology 133:1437~1444
Lai CL / 2007 / Telbivudine versus lamivudine in patients with chronic hepatitis B / N Engl J Med 357:2576~2588
Zeuzem S / 2009 / Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B / J Hepatol 51:11~20
Park H / 2013 / Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir / World J Gastroenterol 19:7671~7679
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]
Journal of Pharmaceutical Investigation
2019 .01
-
eGFR(estimated Glomerular Filtration Rate)로 대표되는 신기능 감소의 원인으로서의 농약 노출
대한직업환경의학회 학술대회 논문집
2020 .11
-
Current Status of Estimated Glomerular Filtration Rate Reporting in Korea
Journal of Laboratory Medicine And Quality Assurance
2019 .01
-
Psychosocial stress and changes in estimated glomerular filtration rate among adults with diabetes mellitus
Kidney Research and Clinical Practice
2015 .01
-
Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver
2017 .01
-
Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
Tuberculosis and Respiratory Diseases
2019 .01
-
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Cancer Research and Treatment
2020 .01
-
Effect of estimating equations for glomerular filtration rate on novel surrogate markers for renal outcome
Kidney Research and Clinical Practice
2021 .01
-
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer
Cancer Research and Treatment
2024 .01
-
Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non–Small Cell Lung Cancer: Single-Institution Experience
Cancer Research and Treatment
2024 .07
-
Association of Pre- and Post-Donation Renal Function with Midterm Estimated Glomerular Filtration Rate in Living Kidney Donors: A Retrospective Study
Yonsei Medical Journal
2023 .03
-
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer
Cancer Research and Treatment
2022 .01
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification
Yonsei Medical Journal
2018 .01
-
GC1118, a new EGFR targeting antibody, in patient derived xenograft model of KRAS mutation colorectal cancer and EGFR viii expressed glioblastoma
한국실험동물학회 학술발표대회 논문집
2016 .08
-
The application of transgenic mice with mutant EGFR in drug development and biological role
한국실험동물학회 학술발표대회 논문집
2022 .01
-
Clinical Characteristics and Continued Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Administration in EGFR-Mutated Non-small Cell Lung Cancer with Skeletal Metastasis
Cancer Research and Treatment
2016 .01
-
성인의 신체활동과 평가 사구체 여과율과의 관계
Korean Journal of Family Practice
2019 .01
-
Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
Yonsei Medical Journal
2017 .01
-
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Cancer Research and Treatment
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0